AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01115322 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: No Treatment with UVA and UVB and visible light irradiation
Description: Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study NCT00935246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
Study NCT03840434 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MyotonPRO
Description: Each patient will perform a stress test to trigger the painful. Measurements will be done by intramuscular punction as usually, and by non invasive tool : MyotonPRO
Study NCT02587182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Dry needling
Description: The muscles were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the myofascial trigger point, eliciting local twitch responses in some insertions
Study NCT02199717 — intervention group
Intervention type: DEVICE
Intervention: Accelerometer
Study NCT01546623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP-144-SR(6M)
Study NCT01546623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP-144-SR(3M)
Study NCT01439438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate coated tablet
Description: Test formulation
Study NCT01439438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® coated tablet
Description: Reference formulation
Study NCT02002260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel intrauterine system
Study NCT03417128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: Participants residing in the location selected to be intervene will to form at minimum 4 peer groups. This group will receive a continuous three-months, peer-led nutrition and lifestyle behaviour intervention through a series of peer gathering. Two participants from each peer group will be selected as the peer leader (PL). PL will be trained to deliver the content of PERSUADE modules and will be responsible to run a weekly peer gathering with their respective groups for the following three months.
Study NCT01311908 — intervention group
Intervention type: PROCEDURE
Intervention: Methods of gastrojejunostomy reconstruction
Description: Roux-en-Y reconstruction in pancreaticoduodenectomy
Study NCT03804359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: In the personalized arm, the patient will be treated in function of the CysR activity result during the inclusion visit.
Study NCT02002260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined oral contraceptives
Study NCT01178645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, etoposide, cytarabine, and melphalan
Description: Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
Study NCT02017574 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reaching Task
Description: Learn a reaching task that requires coordination of the arm segments
Study NCT02017574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reaching Task
Description: Learn a reaching task that requires coordination of the arm segments
Study NCT02986087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal Tracheal Occlusion
Description: Fetuses with congenital diaphragmatic hernia with an observed to expected lung-to-head ratio of \<25%, LHR \<1, o/e LHR\<30% (moderate), singleton pregnancy, no known other anomalies, gestational age \< 29 weeks 6 days, no maternal disease, maternal age > 18 years old meet criteria to be offered tracheal occlusion. We want to test feasibility and efficacy in our center as a requirement to enter the TOTAL trial.
Study NCT02091609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dental interproximal brush
Description: use of this to maintain oral hygiene
Study NCT03265080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADXS-NEO
Description: Intravenous infusion
Study NCT03265080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study NCT02091609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dental floss
Description: use of this to maintain oral hygiene
Study NCT01301430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1PV
Description: H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).
Study NCT01671514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epicatechin-enriched dark chocolate
Description: For experimental purposes, subjects will take one square of epicatechin-enriched dark chocolate per day for 90 days.
Study NCT01671514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-epicatechin dark chocolate
Description: As a placebo control, subjects will take 1 square of low-epicatechin chocolate per day for 90 days.
Study NCT01097993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-fermented dairy product
Description: Arm 1 - Intervention 1 (probiotics)
Study NCT01097993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2- milk-based non-fermented dairy product (control product)
Description: Arm 2 - Intervention 2 (control)
Study NCT01421030 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous pulmonary valve implantation or open heart surgery
Description: Outcomes before percutaneous pulmonary valve implantation or open heart surgery before, 1, 3, 6 and 12 months after the treatment
Study NCT04691830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prosody treatment program
Description: The prosody treatment program is an evidence-based practice targeting receptive and expressive prosodic skills in addition to speech production, intelligibility, pragmatics and phonology. The program incorporates the principles of validated prosodic rehabilitation strategies such as Dynamic Temporal and Tactile Cueing (DTTC), Melodic Intonation Therapy, Lee Silverman Voice Treatment in addition to expert professional practice.~The program was applied using a systematic approach of providing cues to help accelerate the child's learning of the prosodic skills targeted in the program. The program is divided into two sections according to the age into preschool section and school age section.
Study NCT04691830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional auditory and language rehabilitation
Description: Auditory rehabilitation therapy included activities targeting auditory skills: sound detection, discrimination, identification and auditory comprehension. Language rehabilitation targeted improving semantics, syntax, pragmatics and phonology.
Study NCT04691830 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional auditory and language rehabilitation
Description: Auditory rehabilitation therapy included activities targeting auditory skills: sound detection, discrimination, identification and auditory comprehension. Language rehabilitation targeted improving semantics, syntax, pragmatics and phonology.
Study NCT01233232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose bid
Study NCT01233232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069 50mg
Description: Oral dose bid
Study NCT01233232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069 80mg
Description: Oral dose bid
Study NCT02646371 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexyn2a
Description: 2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
Study NCT03016533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir film-coated tablets
Description: Dolutegravir film-coated tablets will be provided as 50 mg tablets.
Study NCT03016533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir film-coated dispersible tablets
Description: Dolutegravir film-coated dispersible tablets will be provided as 5 mg dispersible tablets. It will be administered at the appropriate dose as determined by results of the parent protocol to participants as per their age and weight band.
Study NCT03016533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/DTG/3TC immediate release tablets
Description: ABC/DTG/3TC immediate release tablets will be provided as biconvex, oval tablets containing 600 mg ABC, 50 mg DTG and 300 mg 3TC.
Study NCT02646371 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of TBS solution will be injected intramuscularly 4 weeks apart
Study NCT03016533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/DTG/3TC film-coated dispersible tablets
Description: ABC/DTG/3TC dispersible tablets will be provided as biconvex, oval, film-coated tablets containing 60 mg ABC, 5 mg DTG and 30 mg 3TC.
Study NCT02588677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib (4.5)
Description: 4.5 mg/kg/day
Study NCT02588677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Study NCT02588677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Study NCT02588677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02588677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib (3.0)
Description: 3 mg/kg/day
Study NCT03042988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heating pad
Description: Heat stress applied on the trunk for up to 8 hours
Study NCT03042988 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: heating pad turned off applied on the trunk for up to 8 hours
Study NCT04247308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Stimulation
Description: Auditory, tactile, visual, vestibular and oro motor stimulation
Study NCT04247308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement therapy
Description: Passive range of movements, antigravity movements in prone and supine
Study NCT04247308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine hospital care
Description: Maintaining the vitals
Study NCT02346097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)
Description: Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to Arm descriptions
Study NCT02346097 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)
Description: Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to Arm descriptions
Study NCT01701024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACYC
Description: ACYC active, topically applied to the face for 12 weeks
Study NCT01701024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACYC vehicle
Description: ACYC vehicle (placebo), topically applied to the face for 12 weeks
Study NCT01271530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Limb Ergometry
Description: Cardiovascular training will be performed using upper limb ergometers at home for 8 weeks. Each subject will receive an individually prescribed programme and will begin exercising for at least ten minutes per day three days per week. If an individual has difficulty exercising for 10 minutes continuously, the 10 minute session may be broken into 2-3 minute bursts of exercise, with one minute rests. Subjects will aim to increase exercise durations to 20 minutes per day five days per week and will exercise at moderate to high intensities.
Study NCT02879682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nTMS data available for the surgeon
Description: the preoperatively acquired map of the motor cortex by nTMS will be available for the surgeon
Study NCT02879682 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: nTMS data not available for the surgeon
Description: the preoperatively acquired map of the motor cortex by nTMS will not be available for the surgeon
Study NCT02221765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP1420
Description: Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
Study NCT02221765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% (w/v) saline single-dose, administered subcutaneously
Study NCT04636983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin IV
Study NCT04636983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT02558647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for insomnia (CBT-I)
Description: CBT-I is an online, fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
Study NCT02558647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-Education about Sleep (PE)
Description: PE provides online information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
Study NCT01301989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Counselor Intervention
Description: Families in the sleep counselor arm of the study will receive 3 scheduled home visits by a trained sleep counselor during the first 3 months following enrollment. Two optional home visits may be scheduled to help families encountering ongoing barriers to improving their child's sleep. The intervention will be provided by trained, bilingual, culturally competent sleep counselors, who will assess home sleep conditions, work with the family to teach them how to improve sleep hygiene and the sleep environment, provide equipment as needed to improve the sleep environment (e.g. nightlight, inflatable bed, window shade, etc.) and guide the family to begin setting goals and making decisions to initiate and sustain behavioral and environmental changes to improve sleep.
Study NCT01301989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education Control
Description: The control group will receive a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, Information about Children's Sleep for Parents and Teachers
Study NCT02956772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed. Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid. Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
Study NCT02956772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed. Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid. Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
Study NCT02956772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Arsenic trioxide 10 mg is put into 500 ml saline solution and then administrated by continuous intravenous drip for 5 hours during a treatment day.
Study NCT02815813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PeerFIT
Description: The 12-month PeerFIT intervention consists of a 6-month intensive phase including: (a) once weekly 60-minute group weight management and exercise session led by a lifestyle coach; (b) once weekly one-hour physical activity session delivered in community settings; and (c) Facebook and mHealth technology (i.e., Fitbits, text messaging support) to increase motivation and facilitate self-monitoring and peer social support for health behavior change. Participants then transition to a 6-month lower intensity phase in which the 90-minute weight management sessions are discontinued. The groups will be conducted as open groups with a minimum of 4 and maximum of 18 participants at any given time.
Study NCT02815813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BEAT
Description: Participants in BEAT will receive monthly individual lifestyle sessions delivered by a lifestyle coach including education, guidance, and support for self-monitoring behaviors (i.e., daily self-weighing and tracking daily steps) during the first six months of the study, plus text message reminders and encouragement for self-monitoring weight loss behaviors during the entire 12-month study period. Participants will receive materials with tips and strategies for healthy eating and increasing physical activity. They will also be given a wearable activity tracker (i.e., Fitbit Zip) to use with instructions for using the device. The first session with the lifestyle coach will be in person and thereafter by phone.
Study NCT04125238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: Participants will generate descriptions of vivid positive future events.
Study NCT04125238 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Episodic Thinking
Description: Participants will generate descriptions of vivid positive recent past events.
Study NCT04626596 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiopaque Etonogestrel (ENG) Implant
Description: 68 mg subdermal implant
Study NCT04206241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care early infant diagnosis (POC EID)
Description: HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
Study NCT04273906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End-range mobilization
Description: End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
Study NCT04273906 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: End-range mobilization
Description: End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
Study NCT04273906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo technique
Description: Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
Study NCT04273906 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo technique
Description: Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
Study NCT02320487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m\^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2-6.
Study NCT02320487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2-6.
Study NCT03099720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: local anesthetic will be given locally at the site of operation to decrease the level of pain after operation
Study NCT03099720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo fluid will be given at the site of operation locally
Study NCT03553186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100 MG/ML
Description: TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
Study NCT03553186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution (200 cc sterile normal saline + placebo TXA ampule (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
Study NCT01195337 — intervention group
Intervention type: BEHAVIORAL
Intervention: PA Prescription Plan
Description: Exercise program and instructions.
Study NCT01195337 — intervention group
Intervention type: DEVICE
Intervention: Pedometer
Description: Step monitor for individual PA progress.
Study NCT01195337 — intervention group
Intervention type: BEHAVIORAL
Intervention: Newsletters
Description: 4 Newsletters with topics based on PA progression phases of adoption and maintenance.